Table I.
Characteristics of the eligible studies included in the meta-analysis.
| Author | Year | Tp | Fp | Fn | Tn | Disease | Method | Threshold | Ref. |
|---|---|---|---|---|---|---|---|---|---|
| Xu | 2008 | 88 | 7 | 136 | 754 | Breast cancer | CLIA | 2 pmol/l | (33) |
| Xu | 2009 | 51 | 12 | 29 | 88 | CLL | CLIA | 2 pmol/l | (19) |
| Luo | 2009 | 15 | 1 | 12 | 29 | RCC | CLIA | 2 pmol/l | (12) |
| Nisman | 2010 | 63 | 2 | 100 | 18 | RCC | CLIA | 2 pmol/l | (34) |
| Li | 2010 | 63 | 8 | 38 | 87 | Lung cancer | CLIA | 2 pmol/l | (9) |
| Nisman | 2010 | 91 | 14 | 70 | 106 | Breast cancer | CLIA | 2 pmol/l | (36) |
| Carlsson | 2009 | 34 | 11 | 71 | 89 | Breast cancer | ELISA | 12.3 U/l | (37) |
| McKenna | 1988 | 44 | 112 | 26 | 63 | Breast cancer | ELISA | 12.3 U/l | (38) |
| Alegre | 2012 | 79 | 6 | 18 | 12 | Breast cancer | IHC | (39) | |
| Romain | 2000 | 169 | 10 | 42 | 15 | Breast cancer | IHC | (40) | |
| Walther | 1993 | 10 | 2 | 16 | 18 | Head and neck cancer | REA | 5 U/l | (32) |
| Di Raimondo | 2001 | 173 | 7 | 15 | 23 | CLL | REA | 5 U/l | (41) |
| Vrzalova | 2009 | 10 | 1 | 9 | 19 | Ovarian cancer | REA | 5 U/l | (42) |
| Votava | 2007 | 27 | 10 | 17 | 40 | ALL | REA | 5 U/l | (43) |
| Svobodova | 2007 | 181 | 5 | 154 | 95 | Breast cancer | REA | 5 U/l | (44) |
Tp, true-positive; Fp, false-positive; Fn, false-negative; Tn, true-negative; CLIA, chemiluminescence immunoassay; CLL, chronic lymphocytic leukemia; RCC, renal cell carcinoma; ELISA, enzyme-linked immunosorbent assay; IHC, immunohistochemistry; REA, radioenzymatic assay; ALL, acute lymphoblastic leukemia.